Tigecycline

2005 ◽  
Vol 40 (10) ◽  
pp. 897-907 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The October 2005 monograph topics are ramelteon, lidocaine/tetracaine patch, dapsone gel, altrasentan, and deferasirox. The DUE is on ramelteon.

Lanthanum Carbonate

2005 ◽  
Vol 40 (3) ◽  
pp. 250-261
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The March 2005 monograph topics are ziconotide, eszopiclone, palifermin, paclitaxel, and darifenacin. The DUE is on eszopiclone.

Micafungin Sodium

2005 ◽  
Vol 40 (8) ◽  
pp. 693-704
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Pulmonary Arterial ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2005 monograph topics are sildenafil citrate for pulmonary arterial hypertension, paracalcitol capsules, galsulfase, dalbavancin, and febuxostat. The DUE is on paricalcitol capsules.

Exenatide Injection

2005 ◽  
Vol 40 (11) ◽  
pp. 994-1003
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation ◽  
Ophthalmic Suspension

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2005 monograph topics are pregabalin, nepafenac ophthalmic suspension, mecasermin (rDNA origin) injection, abatacept, and rimonabant. The DUE is on pregabalin.

Rotigotine Transdermal System

2007 ◽  
Vol 42 (10) ◽  
pp. 939-950 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Rotigotine Transdermal System ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD-ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The October 2007 monograph topics are maraviroc, etravirine, bifeprunox, regadenoson, and fesoterodine. The DUE is on maraviroc.

Aliskiren

2007 ◽  
Vol 42 (8) ◽  
pp. 737-750 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation ◽  
Formoterol Fumarate

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD-ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2007 monograph topics are temsirolimus, formoterol fumarate inhalation solution, levocetirizine, ambrisentan, and raltegravir. The DUE is on temsirolimus.

Eszopiclone

2005 ◽  
Vol 40 (5) ◽  
pp. 430-442
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Immune Globulin ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2005 monograph topics are micafungin sodium, pramlintide acetate, vaccinia immune globulin intravenous, tipranavir, and sildenafil citrate. The DUE is on micafungin sodium.

Mesalamine

2007 ◽  
Vol 42 (6) ◽  
pp. 543-552 ◽  
Author(s):  
Dennis J. Cada ◽  
Danial E. Baker ◽  
Terri Levien
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Lisdexamfetamine Dimesylate ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD-ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2007 monograph topics are lapatinib, aliskiren, lisdexamfetamine dimesylate, telavancin, and ambrisentan. The DUE is on aliskiren.

Conivaptan

2006 ◽  
Vol 41 (5) ◽  
pp. 455-464
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Rotavirus Vaccine ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2006 monograph topics are anidulafungin, selegiline transdermal system, lubiprostone, mecasermin rinfabate injection, and rotavirus vaccine. The DUE is on anidulafungin.

Granisetron Transdermal System

2009 ◽  
Vol 44 (4) ◽  
pp. 332-339 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Proton Pump ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Fibrinogen Concentrate ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The April 2009 monograph topics are dexlansoprazole, milnacipran, oxybutynin chloride 10% gel, fibrinogen concentrate (human), and ecallantide injection. The DUE is on proton pump inhibitors.

Clevidipine Butyrate Injectable Emulsion

2008 ◽  
Vol 43 (11) ◽  
pp. 903-912 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2008 monograph topics are on romiplostim, rivaroxaban, golimumab, dronedarone, and degarelix. The DUE is on romiplostim.

Sign in / Sign up

Export Citation Format

Share Document